This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tauber, M. Articles by Rochiccioli, P. Search for Related Content PubMed PubMed Citation Articles by Tauber, M. Articles by Rochiccioli, P. Pubmed/NCBI databases Compound via MeSH Substance via MeSH

Can Some Growth Hormone (GH)-Deficient Children Benefit from Combined Therapy with Gonadotropin-Releasing Hormone Analogs and GH? Results of a Retrospective Study

Unité d’Endocrinologie, Hôpital des Enfants, 31026 Toulouse, France

Address all correspondence and requests for reprints to: Dr. M. Tauber, Hopital des Enfants, 330 avenue de Grande Bretagne, BP3119, 31026 Toulouse, France. E-mail: tauber.mt{at}chu-toulouse.fr.

Abstract

Recombinant GH (rGH) treatment does not invariably correct height deficits in GH-deficient children once puberty has begun. The addition of GnRH analogs (GnRHa) to delay puberty has been advocated, but published results are few and sometimes conflicting.

We retrospectively compared GH-deficient children treated with rGH and GnRHa for at least 1 yr after entering puberty and having attained their final height (n = 23) with a matched control group treated only with rGH. Overall, combined therapy did not significantly increase final height relative to rGH alone. However, the shortest girls at the onset of puberty (<25th percentile) benefited more than the tallest (>75th percentile) in both final height relative to predicted height and pubertal catch-up growth.

In the control group, patients having experienced intrauterine growth retardation (IUGR) attained a lower mean final height than patients without IUGR (difference significant in boys, but not in girls). In the combined therapy group, IUGR did not affect the final height of either sex.

Our results suggest that two populations might benefit most from combined GnRHa and rGH therapy: girls particularly short at the onset of puberty and patients who had experienced IUGR. Further prospective studies are required to confirm these preliminary hypothesis.

Footnotes

Abbreviations: GHD, GH deficient, GH deficiency; GnRHa, GnRH analog; IUGR, intrauterine growth retardation; rGH, recombinant GH; SDS, SD score(s).

This article has been cited by other articles:

				M. J. E. Walenkamp, A. M. Pereira, W. Oostdijk, W. H. Stokvis-Brantsma, R. W. Pfaeffle, O. Blankenstein, and J. M. Wit Height Gain with Combined Growth Hormone and Gonadotropin-Releasing Hormone Analog Therapy in Two Pubertal Siblings with a Growth Hormone-Releasing Hormone Receptor Mutation J. Clin. Endocrinol. Metab., January 1, 2008; 93(1): 204 - 207. [Abstract] [Full Text] [PDF]